The application of epigenetic modifiers on the treatment of prostate and bladder cancer

Zhengwang Zhang, Jose Karam, Eugene P Frenkel, Arthur I Sagalowsky, Jer-Tsong Hsieh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Prostate cancer and transitional cell carcinoma (TCC) of bladder are the 2 most common malignancies in the male adult urogenital system. Epigenetic gene silencing, particularly tumor suppressor genes, has become a new area of cancer research. Agents such as deoxyribonucleic acid methyltransferase inhibitors or histone deacetylase inhibitors are epigenetic modifiers that can restore gene expression and alter the malignant phenotype of cancer. They provide a new therapeutic avenue for prostate cancer and TCC. It is also likely that combination regimens using epigenetic modifiers with other classes of agents may have higher therapeutic efficacy for prostate cancer and TCC, especially metastatic and/or refractory cases. We review current knowledge of epigenetic event in prostate cancer and TCC, and discuss the possible clinical implications for these 2 diseases.

Original languageEnglish (US)
Pages (from-to)152-160
Number of pages9
JournalUrologic Oncology: Seminars and Original Investigations
Volume24
Issue number2 SPEC. ISS.
DOIs
StatePublished - Mar 2006

Fingerprint

Transitional Cell Carcinoma
Urinary Bladder Neoplasms
Epigenomics
Prostatic Neoplasms
Urogenital System
Neoplasms
Histone Deacetylase Inhibitors
Methyltransferases
Gene Silencing
Tumor Suppressor Genes
Urinary Bladder
Phenotype
Gene Expression
DNA
Therapeutics
Research

Keywords

  • Bladder cancer
  • Deoxyribonucleic acid methyltransferase
  • Epigenetics
  • Histone deacetylase
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

The application of epigenetic modifiers on the treatment of prostate and bladder cancer. / Zhang, Zhengwang; Karam, Jose; Frenkel, Eugene P; Sagalowsky, Arthur I; Hsieh, Jer-Tsong.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 24, No. 2 SPEC. ISS., 03.2006, p. 152-160.

Research output: Contribution to journalArticle

@article{a6790e66f47546bba89e6e49bee47c51,
title = "The application of epigenetic modifiers on the treatment of prostate and bladder cancer",
abstract = "Prostate cancer and transitional cell carcinoma (TCC) of bladder are the 2 most common malignancies in the male adult urogenital system. Epigenetic gene silencing, particularly tumor suppressor genes, has become a new area of cancer research. Agents such as deoxyribonucleic acid methyltransferase inhibitors or histone deacetylase inhibitors are epigenetic modifiers that can restore gene expression and alter the malignant phenotype of cancer. They provide a new therapeutic avenue for prostate cancer and TCC. It is also likely that combination regimens using epigenetic modifiers with other classes of agents may have higher therapeutic efficacy for prostate cancer and TCC, especially metastatic and/or refractory cases. We review current knowledge of epigenetic event in prostate cancer and TCC, and discuss the possible clinical implications for these 2 diseases.",
keywords = "Bladder cancer, Deoxyribonucleic acid methyltransferase, Epigenetics, Histone deacetylase, Prostate cancer",
author = "Zhengwang Zhang and Jose Karam and Frenkel, {Eugene P} and Sagalowsky, {Arthur I} and Jer-Tsong Hsieh",
year = "2006",
month = "3",
doi = "10.1016/j.urolonc.2005.11.004",
language = "English (US)",
volume = "24",
pages = "152--160",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2 SPEC. ISS.",

}

TY - JOUR

T1 - The application of epigenetic modifiers on the treatment of prostate and bladder cancer

AU - Zhang, Zhengwang

AU - Karam, Jose

AU - Frenkel, Eugene P

AU - Sagalowsky, Arthur I

AU - Hsieh, Jer-Tsong

PY - 2006/3

Y1 - 2006/3

N2 - Prostate cancer and transitional cell carcinoma (TCC) of bladder are the 2 most common malignancies in the male adult urogenital system. Epigenetic gene silencing, particularly tumor suppressor genes, has become a new area of cancer research. Agents such as deoxyribonucleic acid methyltransferase inhibitors or histone deacetylase inhibitors are epigenetic modifiers that can restore gene expression and alter the malignant phenotype of cancer. They provide a new therapeutic avenue for prostate cancer and TCC. It is also likely that combination regimens using epigenetic modifiers with other classes of agents may have higher therapeutic efficacy for prostate cancer and TCC, especially metastatic and/or refractory cases. We review current knowledge of epigenetic event in prostate cancer and TCC, and discuss the possible clinical implications for these 2 diseases.

AB - Prostate cancer and transitional cell carcinoma (TCC) of bladder are the 2 most common malignancies in the male adult urogenital system. Epigenetic gene silencing, particularly tumor suppressor genes, has become a new area of cancer research. Agents such as deoxyribonucleic acid methyltransferase inhibitors or histone deacetylase inhibitors are epigenetic modifiers that can restore gene expression and alter the malignant phenotype of cancer. They provide a new therapeutic avenue for prostate cancer and TCC. It is also likely that combination regimens using epigenetic modifiers with other classes of agents may have higher therapeutic efficacy for prostate cancer and TCC, especially metastatic and/or refractory cases. We review current knowledge of epigenetic event in prostate cancer and TCC, and discuss the possible clinical implications for these 2 diseases.

KW - Bladder cancer

KW - Deoxyribonucleic acid methyltransferase

KW - Epigenetics

KW - Histone deacetylase

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=33644753715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644753715&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2005.11.004

DO - 10.1016/j.urolonc.2005.11.004

M3 - Article

C2 - 16520279

AN - SCOPUS:33644753715

VL - 24

SP - 152

EP - 160

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 2 SPEC. ISS.

ER -